Cabozantinib is a small molecule inhibitor of the tyrosine kinases c-Met and Vascular endothelial growth factor receptor-2 (VEGFR2).
Cabozantinib has been shown to reduce tumor growth, metastasis, and angiogenesis.
It was formerly known as XL184.
It was developed by Exelixis Inc and is marketed under trade name Cometriq.
Cabozantinib has been already approved by the US Food & Drug Administration for the treatment of medullary thyroid cancer and it is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular and kidney cancers.
Safety and effects in children are not yet known.